ArticleFrontiers in endocrinology2026
Association between C-reactive protein to triglyceride-glucose index and atrial fibrillation: a cross-sectional analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between a novel composite biomarker, the C-reactive protein to triglyceride-glucose index (CTI) and the prevalence of atrial fibrillation (AF) in a general adult population. Methods: This cross-sectional study included 2, 988 participants Clinical and laboratory data were collected to calculate the CTI. Multivariable logistic regression models were employed to evaluate the association between CTI and AF prevalence, and the dose-response relationship was assessed using restricted cubic spline (RCS) analysis. Furthermore, the association between CTI and AF risk was evaluated using the C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Among the 2, 988 participants, CTI levels were significantly higher in the AF group compared to the non-AF group. In the fully adjusted model (adjusting for age, sex, BMI, blood pressure, glycemic indices, and lipid profiles), CTI was independently and positively associated with AF prevalence (OR 7.27, 95% CI 5.87-9.00; P < 0.001). Restricted cubic spline analysis revealed a significant linear dose-response relationship between CTI and AF risk. Furthermore, adding CTI to the reference clinical model improved the C-index from 0.6828 to 0.7985, accompanied by significant improvements in the net reclassification improvement (NRI: 0.5609) and integrated discrimination improvement (IDI: 0.7182) (all P < 0.001). Conclusions: A higher CTI, reflecting a state of combined elevated inflammation and insulin resistance, is significantly and independently associated with an increased prevalence of atrial fibrillation. This novel index may serve as a valuable and integrative biomarker for identifying individuals at high risk for AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.